Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke
- 2 September 2011
- journal article
- research article
- Published by Elsevier BV in Brain Research
- Vol. 1410, 120-121
- https://doi.org/10.1016/j.brainres.2011.07.001
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate modelBrain Research, 2011
- Clinical perspectives of PARP inhibitorsPharmacological Research, 2005
- Ischemic Nitric Oxide and Poly (ADP-Ribose) Polymerase-1 in Cerebral Ischemia: Male Toxicity, Female ProtectionJournal of Cerebral Blood Flow & Metabolism, 2005
- Functional and Histological Evidence for the Protective Effect of NXY-059 in a Primate Model of Stroke When Given 4 Hours After OcclusionStroke, 2003
- Recommendations for Clinical Trial Evaluation of Acute Stroke TherapiesStroke, 2001
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Role of poly(ADP-ribose) synthetase in inflammation and ischaemia–reperfusionTrends in Pharmacological Sciences, 1998
- Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)PolymeraseJournal of Cerebral Blood Flow & Metabolism, 1997
- Inhibition of poly (ADP-ribose) Synthetase Attenuates Neutrophil Recruitment and Exerts Antiinflammatory EffectsThe Journal of Experimental Medicine, 1997
- Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemiaNature Medicine, 1997